dc.contributor.author
Al-Rasheed, Nawal M.
dc.contributor.author
Al-Rasheed, Nouf M.
dc.contributor.author
Hasan, Iman H.
dc.contributor.author
Al-Amin, Maha A.
dc.contributor.author
Al-Ajmi, Hanaa N.
dc.contributor.author
Mohamad, Raeesa A.
dc.contributor.author
Mahmoud, Ayman M.
dc.date.accessioned
2018-06-08T11:07:38Z
dc.date.available
2017-10-26T14:30:59.208Z
dc.identifier.uri
https://refubium.fu-berlin.de/handle/fub188/21666
dc.identifier.uri
http://dx.doi.org/10.17169/refubium-24954
dc.description.abstract
Simvastatin is a lipid-lowering agent used to treat hypercholesterolemia and
to reduce the risk of heart disease. This study scrutinized the beneficial
effects of simvastatin on experimental diabetic cardiomyopathy (DCM), pointing
to the role of hyperglycemia-induced oxidative stress and inflammation.
Diabetes was induced by intraperitoneal injection of streptozotocin and both
control and diabetic rats received simvastatin for 90 days. Diabetic rats
showed significant cardiac hypertrophy, body weight loss, hyperglycemia, and
hyperlipidemia. Serum creatine kinase MB (CK-MB) and troponin I showed a
significant increase in diabetic rats. Simvastatin significantly improved body
weight, attenuated hyperglycemia and hyperlipidemia, and ameliorated CK-MB and
troponin I. Simvastatin prevented histological alterations and deposition of
collagen in the heart of diabetic animals. Lipid peroxidation and nitric oxide
were increased in the heart of diabetic rats whereas antioxidant defenses were
decreased. These alterations were significantly reversed by simvastatin. In
addition, simvastatin decreased serum inflammatory mediators and expression of
NF-κB in the diabetic heart. Cardiac caspase-3 was increased in the diabetic
heart and decreased following treatment with simvastatin. In conclusion, our
results suggest that simvastatin alleviates DCM by attenuating hyperglycemia
/hyperlipidemia-induced oxidative stress, inflammation, and apoptosis.
en
dc.format.extent
14 Seiten
dc.rights.uri
http://creativecommons.org/licenses/by/4.0/
dc.subject.ddc
600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit
dc.title
Simvastatin Ameliorates Diabetic Cardiomyopathy by Attenuating Oxidative
Stress and Inflammation in Rats
dc.type
Wissenschaftlicher Artikel
dcterms.bibliographicCitation
Oxidative Medicine and Cellular Longevity. - (2017), Art. ID 1092015
dcterms.bibliographicCitation.doi
10.1155/2017/1092015
dcterms.bibliographicCitation.url
http://doi.org/10.1155/2017/1092015
refubium.affiliation
Charité - Universitätsmedizin Berlin
de
refubium.affiliation.other
Klinik für Endokrinologie, Diabetes und Ernährungsmedizin
![Confidence was never recorded for this value](/cache_202e45ad85b55efaeb29160f63cd3f3b/themes/FuCD/images/authority_control/invisible.gif)
refubium.mycore.fudocsId
FUDOCS_document_000000028391
refubium.note.author
Der Artikel wurde in einer Open-Access-Zeitschrift publiziert.
refubium.resourceType.isindependentpub
no
refubium.mycore.derivateId
FUDOCS_derivate_000000009050
dcterms.accessRights.openaire
open access
dcterms.isPartOf.issn
1942-0900
dcterms.isPartOf.issn
1942-0994